Compare GDC & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDC | CVRX |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.0M | 253.2M |
| IPO Year | N/A | 2021 |
| Metric | GDC | CVRX |
|---|---|---|
| Price | $3.84 | $8.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.17 |
| AVG Volume (30 Days) | 35.3K | ★ 216.0K |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | N/A | ★ $55,969,000.00 |
| Revenue This Year | N/A | $11.49 |
| Revenue Next Year | N/A | $16.26 |
| P/E Ratio | $8.67 | ★ N/A |
| Revenue Growth | N/A | ★ 18.44 |
| 52 Week Low | $1.03 | $4.30 |
| 52 Week High | $9.92 | $18.55 |
| Indicator | GDC | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 36.23 |
| Support Level | $3.89 | $8.82 |
| Resistance Level | $4.53 | $9.63 |
| Average True Range (ATR) | 0.43 | 0.66 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 27.68 | 2.09 |
GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.